TickerGuard
Buy Day today: Good (67) Broad market participation · no major macro event

Halozyme Therapeutics Inc (HALO)

Healthcare Biotechnology
82.30 $
-0.3% vs. previous close
Closing price · As of: 3. Aug 2026

Halozyme Therapeutics Inc (HALO) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q1 26), "Total Assets" came in at 2,673 million USD. Tick rows to compare them in a chart.

Income Statement Balance Sheet Cash Flow
Annual Quarterly

All figures in millions of USD.

Balance Sheet HALO
Tick rows to compare them in a chart (up to 4) Q2 23 Q3 23 Q4 23 Q1 24 Q2 24 Q3 24 Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26
1,810 1,893 1,733 1,842 1,969 2,118 2,063 2,197 2,054 2,221 2,525 2,673
766 879 746 874 988 1,127 1,085 1,262 1,123 1,329 825 1,003
221 274 118 165 188 154 116 176 62 420 134 310
348 483 336 463 529 666 596 748 548 702 143 319
246 217 234 196 215 286 308 305 316 346 441 458
132 129 128 169 159 131 142 165 182 186 176 155
75 75 – – – – – – – – – –
417 417 417 417 417 417 417 417 417 417 580 582
511 491 473 455 437 420 402 384 366 349 981 952
1,659 1,643 1,649 1,664 1,680 1,665 1,700 1,714 1,721 1,717 2,477 2,453
116 115 112 132 133 109 139 150 134 837 177 363
34 32 32 32 31 – – – – 711 – 209
10 19 12 13 15 12 10 20 19 15 21 14
1,496 1,498 1,499 1,501 1,503 1,504 1,506 1,507 1,509 800 2,143 1,936
151 249 84 178 289 453 364 482 333 504 49 220
140 222 91 167 261 398 360 478 361 502 55 205
134 134 131 129 129 130 129 127 124 122 118 123

Data as of: August 3, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?